Seasonal allergic rhinitis
Conditions
Interventions
investigational material(s)
Generic name etc : HP-3060 (Emedastine fumarate)
INN of investigational material : emedastine
Therapeutic category code : 449 Other antiallergic agents
Dosage and Administr
Sponsors
Hisamitsu Pharmaceutical Co., Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Patients with a diagnosis of seasonal allergic rhinitis and symptoms of this condition for at least two years.
Exclusion criteria
Exclusion criteria: - Patients with rhinosinusitis or with any type of rhinitis other than allergic rhinitis, including vasomotor rhinitis and non-allergic rhinitis with eosinophilia. - Patients with polyps or polyp-like lesions that could influence assessment of nasal obstruction. - Patients with adenoid hypertrophy or nasal malformations (deviation of the nasal septum, hypertrophic rhinitis, or choanal atresia) that could influence assessment of nasal obstruction. - Patients receiving hyposensitization therapy or nonspecific immunotherapy who have not reached the maintenance stage. - Patients with a history of hypersensitivity to emedastine, levocetirizine, or piperazine derivatives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety | — |
Outcome results
None listed